Skip to content
Biodatica
Start free

AstraZeneca

Detroit, Michigan

OncologyantibodyPhase IIListed · AZN

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

7w agoTrial registeredMay 27, 2026Source filing (opens the source filing in a new tab)

Momentum

81no change

Momentum 81 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Oct 13, 2025

    Advanced Unresectable Melanoma, Metastatic Melanoma · RECRUITING · sponsor: Kevin Kim, MD · Mirdametinib in Patients With Advanced NF1-mutant Melanoma

    ClinicalTrials.gov · NCT07237100 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Mar 30, 2017

    Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: National Cancer Institute (NCI) · Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

    ClinicalTrials.gov · NCT02849496 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Dec 14, 2007

    Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer · COMPLETED · sponsor: AstraZeneca · A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

    ClinicalTrials.gov · NCT00600496 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources